Login / Signup

Tripterygium wilfordii derivative celastrol, a YAP inhibitor, has antifibrotic effects in systemic sclerosis.

Pratyusha ChitturiShiwen XuBahja Ahmed AbdiJohn NguyenDavid E CarterSarthak SinhaRohit AroraJeff BiernaskieRichard J StrattonAndrew Leask
Published in: Annals of the rheumatic diseases (2023)
Our data clarify niches within the skin activated in fibrosis and suggest that compounds, such as celastrol, that antagonise the YAP pathway may be potential treatments for SSc skin fibrosis.
Keyphrases
  • systemic sclerosis
  • interstitial lung disease
  • soft tissue
  • wound healing
  • liver fibrosis
  • rheumatoid arthritis
  • machine learning
  • human health
  • pulmonary fibrosis
  • climate change
  • water soluble
  • artificial intelligence